Report : Middle East and Africa Asthma Spacers Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product (Aerochamber, Optichamber, Volumatic, and Inspirease) and Distribution Channel (Retail Pharmacy, Hospital Pharmacy, and E-Commerce)
At 4.2% CAGR, the Middle East & Africa Asthma Spacers market is speculated to be worth US$ 61.42 million by 2028, says Business Market Insights
According to Business Market Insights’ research, the MEA asthma spacers market was valued at US$ 50.92 million in 2022 and is expected to reach US$ 61.42 million by 2028, registering an annual growth rate of 3.2% from 2022 to 2028. Chronic respiratory conditions becoming more prevalent and patient centric spacer design being given importance are the critical factors attributed to the market expansion.
Spacers play a major role while delivering drugs to the respiratory tract. However, patients face difficulties while using the spacer in some cases due to its size and design. For instance, according to a study conducted by Trudell Medical, one of the significant players in the market in 2019, the majority of the patients feel embarrassed to use spacers because of their size and design. To cope with this problem, market players in the industry are now focusing on the design aspects, which will be easy to carry and offer efficient treatment for respiratory conditions. Therefore, new designs and enhanced features are likely to reshape the asthma spacers market during the forecast period.
On the contrary, high risk of adverse effects due to unlicensed prescriptions hinders the growth of MEA asthma spacers market.
Based on product, the MEA asthma spacers market is segmented into aerochamber, optichamber, volumatic, and inspirease. Aerochamber segment held 43.1% market share in 2022, amassing US$ 21.93 million. It is projected to garner US$ 27.34 million by 2028 to expand at 3.7% CAGR during 2022–2028.
By distribution channel, the MEA asthma spacers market is segmented into retail pharmacy, hospital pharmacy, and E-commerce. With 42.0% share of the domain, the retail pharmacy segment is expected to dominate the market in 2022. It is expected to reach at US$ 21.46 million in 2022 and is estimated to generate US$ 25.49 million by 2028 to grow at a CAGR of 2.9% over the forecast period.
Our regional analysis states that Rest of MEA is expected to capture 45.7% market share in 2022. It is assessed at US$ 23.36 million in 2022 and is likely to hit US$ 27.38 million by 2028, exhibiting a CAGR of 2.7% during the forecast period.
Key players dominating the MEA asthma spacers market are Agaplastic, Cipla Inc., Koninklijke Philips N.V., Koo Medical Equipment, Lupin, Metall Zug, and Teleflex Incorporated among others.
- Cipla Limited announced launching of a new product namely, "Niveoli", that is India's first extra-fine particle beclomethasone-formoterol combination hydrofluoroalkane (HFA) inhaler. The newly launched product is intended for adults, targeting drug delivery to the small airways. Additionally, the new product is a proprietary Cipla inhaler, and the latest offering from Cipla in respiratory inhalation therapy that addresses unmet needs associated with obstructive airway diseases (OAD) such as asthma and chronic obstructive pulmonary disorder (COPD).
- Lupin announced launching of a new product namely, "ADHERO". The newly launched product is a new connected smart device intended for metered-dose inhaler and is first-of-its kind device intended for patients suffering from chronic respiratory diseases by tracking their MDI usage and facilitate for improving adherence to therapy.